Heidrun Katholnigg, executive director of global clinical development Europe for Celerion, a global CRO that specialises in phase I, II and III clinical trials, discusses the acquisition of Assign Group by Celerion in 2016 and the importance of Austria in managing European clinical operations. Furthermore, she highlights the favourable clinical trial environment in Austria and the outstanding service capabilities of Celerion for current and potential partners.
Celerion acquired Assign Group in 2016. What was the rationale behind the acquisition and how has this affected your activities?
"Celerion in Europe is currently diversifying the scope of services it can provide in terms of field of research and this will kick start further growth after this consolidation stage."
